The invention refers to a pharmaceutical compound including an antibody that specifically binds acrylonitrile methylene acrylonitrile / kexina (PCSK9),a. The treatment of acetone characterization or activity for the transformation of methyleneiminase / kexina 9 human (PCSK9) disease or disease by the use of specific PCSK9 antibody or antigen binding fragments, preferably through additional management, has an impact 3-hydroxy-3-methyl-glucose-coa inhibitor3. Reductase (HMG-CoA reductase)； The invention also relates to a specific polychlorinated biphenyl antibody or a binding fragment of its antigen, which is used for treating diseases or diseases affected by the performance or activity of polychlorinated biphenyls. The invention also relates to finished products including packaging materialsSpecific polychlorinated biphenyl antibodies or fragments bound to polychlorinated biphenyl antigensThere is also a label or instruction for which patients can be treated with these antibodies or fragments, and for what dose regime to use. The invention also relates to a method for testing a specific polychlorinated biphenyl9 antibody or a binding part of its antigen to treat certain diseases and specific patient groups.La presente invención se refiere a Composiciones farmacéuticas que comprenden un anticuerpo que se une específicamente a la proproteína convertasa subtilisina/kexina tipo 9 humana (PCSK9), a método para tratar enfermedades o afecciones en las que la expresión o actividad de la proproteína convertasa subtilisina/kexina tipo 9 humana (PCSK9) ocasionan un impacto mediante la administración de anticuerpos específicos para PCSk9 o fragmentos de unión al antígeno de los mismos y preferiblemente mediante la administración adicional de un inhibidor de 3-hidroxi-3-metil-glutaril-CoA reductasa (HMG-CoA reductasa). La presente invención se refiere adicionalmente a anticuerpos específicos para PCSK9 o fragmentos de unión al antígeno de los mismos para su uso en el tratamiento
